潜在首款!科济药业CAR-T疗法拟纳入优先审评

药渡
22 May

来源:药渡撰文:Pharmadeep编辑:维他命2025年5月20日,中国国家药监局药品审评中心(CDE)官网公示,科济药业全资子公司恺兴生命科技申报的舒瑞基奥仑赛注射液拟纳入优先审评,拟用于治疗CLDN18.2表达阳性、至少二线治疗失败的晚期胃/食管胃结合部腺癌。此次优先审评将有助于缩短其上市时间,使患者能够更快地受益于这一创新疗法,为胃癌患者带来了新的希望,也标志着中国CAR-T细胞疗法在实体...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10